OC019—Intrapulmonary Pharmacokinetics (Pk) And The Intracellular Disposition To Support The Long-Lasting Efficacy After An Inhaled Administration Of Its Prodrug Laninamivir Octanoate (Lo)

Abstract

A single inhaled dose of laninamivir octanoate (LO), a long-acting neuraminidase inhibitor, exhibits efficacy to treat both adult and pediatric patients with influenza virus infection. However, the relation between the intrapulmonary pharmacokinetics (PK) of LO and laninamivir, an active metabolite, and its long-lasting efficacy has not fully been investigated. Intrapulmonary pharmacokinetics in healthy volunteers and the intracellular drug disposition in mice were evaluated to clarify the potential mechanism for the prolonged high intrapulmonary retention of laninamivir, which would support its long-lasting efficacy.